|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM30761560X |
| 003 |
DE-627 |
| 005 |
20231225125942.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108385
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1025.xml
|
| 035 |
|
|
|a (DE-627)NLM30761560X
|
| 035 |
|
|
|a (NLM)32173601
|
| 035 |
|
|
|a (PII)S1521-6616(20)30060-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lo, Mindy S
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A framework for understanding Kawasaki disease pathogenesis
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.10.2020
|
| 500 |
|
|
|a Date Revised 04.12.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a CommentIn: Pediatr Res. 2021 Mar;89(4):716-717. - PMID 32492695
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Kawasaki disease (KD) is a common vasculitis of childhood, typically affecting children under the age of five. Despite many aspects of its presentation that bear resemblence to acute infection, no causative infectious agent has been identified despite years of intense scrutiny. Unlike most infections, however, there are significant differences in racial predilection that suggest a strong genetic influence. The inflammatory response in KD specifically targets the coronary arteries, also unusual for an infectious condition. In this review, we discuss recent hypotheses on KD pathogenesis as well as new insights into the innate immune response and mechanisms behind vascular damage. The pathogenesis is complex, however, and remains inadequately understood
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a IL-1
|
| 650 |
|
4 |
|a IgA
|
| 650 |
|
4 |
|a Inflammasome
|
| 650 |
|
4 |
|a Kawasaki disease
|
| 650 |
|
4 |
|a Vasculitis
|
| 650 |
|
7 |
|a Immunoglobulin A
|2 NLM
|
| 650 |
|
7 |
|a Protease Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Matrix Metalloproteinases
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.24.-
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 214(2020) vom: 01. Mai, Seite 108385
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:214
|g year:2020
|g day:01
|g month:05
|g pages:108385
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108385
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 214
|j 2020
|b 01
|c 05
|h 108385
|